MARKET COMPOSITE
Pharmaceuticals: Other Stocks28-30-2024 20:30:00 PM
Price
$105.67
+ 0.40%
The list of companies include ACB-Aurora Cannabis Inc, ACRS-Aclaris Therapeutics Inc, ACRX-Acelrx Pharmaceuticals Inc, ACST-Acasti Pharma Inc, ADMP-Adamis Pharmaceuticals Corp, AGRX-Agile Therapeutics Inc, ALBO-Albireo Pharma Inc, AMPE-Ampio Pharmaceuticals Inc, AMPH-Amphastar Pharmaceuticals Inc, ANIK-Anika Therapeutics Inc., ANIP-ANI Pharmaceuticals Inc, ASMB-Assembly Biosciences Inc, AXSM-Axsome Therapeutics Inc, BHC-Bausch Health Companies Inc, BRBR-Bellring Brands Inc, COLL-Collegium Pharmaceutical Inc, CORT-Corcept Therapeutics Inc, CPIX-Cumberland Pharmaceuticals Inc., CPRX-Catalyst Pharmaceuticals Inc, CRON-Cronos Group Inc, CTIC-CTI BioPharma Corp, CTLT-Catalent Inc., DRRX-Durect Corp, EGRX-Eagle Pharmaceuticals Inc, EVOK-Evoke Pharma Inc, GLMD-Galmed Pharmaceuticals Ltd, HAPP-Happiness Biotech Group Ltd, HEPA-Hepion Pharmaceuticals Inc, HEXO-HEXO Corp, HROW-Harrow Health Inc
* Latest intraday update before market close @ 19:45:41 PM 05/28/2024
Summary
:
Average return is up 0.2%
Median return is down -0.5%
21 out of 46 stocks are up (limited to those with intraday pricing feeds).
Top Movers
:
NAII + 1.5%PCRX + 1.7%AXSM + 2.2%OCUL + 2.6%HROW + 2.8%EGRX + 2.9%VRNA + 3.2%ANIP + 3.5%CPRX + 4.4%MDWD + 8.0%MRNS + 9.1%CORT + 12.1%

Aggregated price index with volume information

Summary:

  • Pharmaceuticals: Other stocks up 0.4% on average while median return up 0.0% in a day
  • Pharmaceuticals: Other stocks down 2.7% on average while median return down 3.0% in a week
  • Pharmaceuticals: Other stocks up 2.8% on average while median return up -2.8% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks
Ticker
1d
7d
30d
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
CORT14.9%
9.5%
38.6%
29.55-0.775.137.72-22%3.3B13%71%76/-4510.0%
MRNS8.7%
11.1%
6.4%
-0.57-0.256.11192.3482.9M12%88%29\-Below support226-0.0%
MDWD8.5%
2.7%
-2.5%
-23.78-0.1827.125.64168.2M0%20%54\/Below support1450.9%
EGRX4.8%
-15.0%
-5.8%
4.345.32.953.0751M13%96%38\/\451-0.2%
SEEL4.5%
-20.6%
-40.3%
9.5624.3M4%27%28/\104-1.0%
CPRX4.4%
-2.1%
11.3%
29.533.334.93-27%2B10%68%58-/-2260.0%
HROW3.7%
10.5%
76.3%
12.737.674.22656.9M9%57%81/-/\Above resistance226-0.3%
VRNA3.2%
-2.7%
-19.7%
-153.512.32645.1M72%28-/\-Below support149-0.1%
ANIP3.1%
2.4%
-3.3%
67.074.622.022.011.3B7%79%45\/\/4510.2%
SNOA2.8%
-11.8%
26.8%
1.290.733.2M1%10%58-\/1060.3%
OCUL2.3%
-5.7%
24.8%
-5.0912.3546.56915.4M10%64%46/-4510.2%
SIGA2.3%
1.1%
-13.2%
6.868.673.963.81542M4%35%43/\/\/2260.3%
AXSM2.1%
-1.1%
7.0%
-12.040.3126.283.7B15%63%54-\/-2260.0%
CRON1.5%
-3.6%
3.5%
-17.881.9861.251B11%17%49/\/2260.1%
SAGE1.3%
6.7%
-12.9%
-1.42-0.261.662.99718M10%92%41/\-\226-0.3%
PCRX1.2%
-1.8%
14.1%
22.80.654.035.9327%1.4B20%118%56/-\226-0.1%
RGLS1.2%
1.7%
-15.5%
-0.132.426.58134.2M10%50%44/-/Below support630.5%
ASMB1.1%
3.7%
12.8%
-0.110.572.0682M10%69%64
SLRX0.9%
-5.3%
-7.0%
0.948.592.3M4%38%44
ANIK0.8%
-3.4%
-3.2%
-4.73100.522.104.40367.7M14%99%40\/\-451-0.0%
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
Detail Performance Summary
  • 1M winners are : Winners for past month are $HROW 76.3%, $SCYX 53.2%, $CORT 38.6%, $OCUL 24.8%, $MDGL 15.5%
  • 1M losers are : Losers for past month are $RGLS -15.5%, $VRNA -19.7%, $RVNC -21.5%, $IRWD -24.8%, $BHC -28.8%
  • 1W winners are : Winners for past week are $MRNS 11.1%, $HROW 10.5%, $CORT 9.5%, $SAGE 6.7%, $MDWD 2.7%
  • 1W losers are : Losers for past week are $SCYX -9.9%, $OGI -11.6%, $ACRS -11.8%, $EGRX -15.0%, $RVNC -15.5%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 5.7%, for the past 3 months is 5.0%

In the past month for a 5 days rolling window, the highest corrrelation is 21.8%, the lowest correlation is -1.6%, the latest correlation is 7.2%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 83.7% between ANIK and IRWD

The lowest correlation is -67.7% between HZNP and ICPT

Stock news

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed

    NASHVILLE, Tenn., May 28, 2024--Revance to Participate in Upcoming Investor Conferences

    PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024. During the conference, Prasha

    Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

    CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conferen

    MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpo

    Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-rel

    As the Q1 earnings season wraps, let's dig into this quarter's best and worst performers in the shelf-stable food industry, including B&G Foods (NYSE:BGS) and its peers.

    Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

    Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.